Business
Expansion of Research Agreement and CIZ1B Update
Expansion of Research Agreement and CIZ1B Update.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n\n10 August 2023\nCizzle Biotechnology Holdings Plc\n(\"Cizzle Biotechnology\" or the \"Company\")\nExpansion of Research Agreement with the University of York for Cancer Diagnosis and Therapy and Update on Progress to Launch CIZ1B Biomarker Early Stage Lung Cancer Test\n \nCizzle Biotechnology, the UK based diagnostics developer, is pleased to announce an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early stage cancer diagnosis, and other potential applications in cancer therapy. This follows significant progress in isolating additional new and specific monoclonal antibodies to the CIZ1B biomarker and incorporating these into a new high-throughput clinical diagnostic immunoassay platform. The recent developments meet key milestones to begin commercial clinical trials. The Company is now engaged in clinical trials design to support the validation and accreditation of the CIZ1B test prior to commercial launch.\n \nHighlights\n\n\n\n\n\n\n\n\n· Successful development of additional specific monoclonal antibodies for CIZ1B Biomarker\n· Application to a new high-throughput immunoassay platform.\n· Significant expansion of current research and development agreement with the University of York, to allow continued access to state of the art facilities and world-leading scientists.\n\n\n\n\n· All intellectual property rights arising from the work to be owned by the Company\n\n\n\n \nCizzle Biotechnology and the University of York have benefited from a long-standing close relationship since the Company was spun out from the University in 2006. That collaboration has continued since the Company was admitted to trading on the London Stock Exchange and currently has a funded programme until 25 September 2024. During this period the team at the University of York under the direction of Professor Dawn Coverley has successfully isolated and validated an additional panel of specific monoclonal antibodies for the CIZ1B biomarker, which is highly associated with early stage lung cancer.\n \nA key milestone for the Company was to take the proof of concept test for CIZ1B and develop an accredited and commercially viable assay that could be used in a laboratory to test for early stage l...